Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2003

Open Access 01-06-2003 | Research article

Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats

Authors: Giuseppe M Campo, PhD, Angela Avenoso, Salvatore Campo, Alida M Ferlazzo, Domenica Altavilla, Alberto Calatroni

Published in: Arthritis Research & Therapy | Issue 3/2003

Login to get access

Abstract

To evaluate the antioxidant activity of the glycosaminoglycans hyaluronic acid (HYA) and chondroitin-4-sulphate (C4S), we used a rat model of collagen-induced arthritis (CIA). Arthritis was induced in Lewis rats by multiple intradermal injections of 250 μl of emulsion containing bovine type II collagen in complete Freund's adjuvant at the base of the tail and into three to five other sites on the back. Rats were challenged again with the same antigen preparation 7 days later. Disease developed about 11 days after the second immunization. The effects of treatment in the rats were monitored by biochemical parameters and by macroscopic and histological evaluations in blood, synovial tissue and articular cartilage. Arthritis produced the following symptoms: severe periarticular erythema, edema and inflammation in the hindpaws; membrane peroxidation in the cartilage of the joints; endogenous antioxidant wasting; high tumour necrosis factor-α (TNF-α) plasma levels; and synovial neutrophil accumulation. Treatment with HYA and C4S, starting at the onset of arthritis for 10 days, limited the erosive action of the disease in the articular joints of knee and paw, reduced lipid peroxidation, restored the endogenous antioxidants reduced glutathione (GSH) and superoxide dismutase, decreased plasma TNF-α levels, and limited synovial neutrophil infiltration. These data confirm that erosive destruction of the joint cartilage in CIA is due at least in part to free radicals released by activated neutrophils and produced by other biochemical pathways. The beneficial effects obtained with the treatment suggest that HYA and C4S could be considered natural endogenous macromolecules to limit erosive damage in CIA or as a useful tool with which to study the involvement of free radicals in rheumatoid arthritis.
Literature
1.
Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell. 1996, 85: 307-310. 10.1016/S0092-8674(00)81109-5.CrossRefPubMed
2.
Jawaheer D, Thomson W, MacGregor AJ, Carthy D, Davidson J, Dyer PA, Silman AJ, Ollier WE: 'Homozygosity' for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum. 1994, 37: 681-6866.CrossRefPubMed
3.
Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 1981, 154: 688-700. 10.1084/jem.154.3.688.CrossRefPubMed
4.
Blake DR, Merry P, Unsworth J, Kidd BL, Outhwaite JM, Ballard R, Morris CJ, Gray L, Lunec J: Hypoxic-reperfusion injury in the inflamed human joint. Lancet. 1989, i: 289-293. 10.1016/S0140-6736(89)91305-6.CrossRef
5.
Lunec J: Free radicals: their involvement in disease processes. Ann Clin Biochem. 1990, 27: 173-182.CrossRefPubMed
6.
Dormandy TL: Free-radical pathology and medicine. A review. J R Coll Physicians Lond. 1989, 23: 221-227.PubMed
7.
Halliwell B, Gutteridge JM: The antioxidants of human extracellular fluids. Arch Biochem Biophys. 1990, 280: 1-8. 10.1016/0003-9861(90)90510-6.CrossRefPubMed
8.
9.
Gambhir JK, Lali P, Jain AK: Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem. 1997, 30: 351-355. 10.1016/S0009-9120(96)00007-0.CrossRefPubMed
10.
Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998, 67: 609-652. 10.1146/annurev.biochem.67.1.609.CrossRefPubMed
11.
Friman C, Eronen I, Videman T: Plasma glycosaminoglycans in experimental osteoarthritis caused by immobilization. J Rheumatol. 1982, 9: 292-294.PubMed
12.
Reddy GK, Dhar SC: Metabolism of glycosaminoglycans in tissue of arthritic rat. Mol Cell Biochem. 1991, 106: 117-124.PubMed
13.
Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000, 19: 333-344. 10.1016/S0945-053X(00)00078-0.CrossRefPubMed
14.
Campo GM, Squadrito F, Altavilla D, Squadrito Giov, Avenoso A, Canale P, Ioculano M, Sperandeo A, Caputi AP: Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidation. J Pharmacol Exp Ther. 1996, 277: 333-340.PubMed
15.
Kroger H, Miesel R, Dietrich A, Ohde M, Altrichter S, Braun C, Ockenfels H: Suppression of type II collagen-induced arthritis by N-acetyl-L-cysteine in mice. Gen Pharmacol. 1997, 29: 671-674. 10.1016/S0306-3623(96)00570-8.CrossRefPubMed
16.
Campo GM, Squadrito F, Campo S, Altavilla D, Quartarone C, Ceccarelli S, Ferlito M, Avenoso A, Squadrito G, Saitta A, Caputi AP: Beneficial effect of Raxofelast, an hydrophilic vitamin E analogue, in the rat heart after ischemia and reperfusion injury. J Mol Cell Cardiol. 1998, 30: 1493-1503. 10.1006/jmcc.1998.0713.CrossRefPubMed
17.
Campo GM, Squadrito F, Ceccarelli S, Calò M, Avenoso A, Campo S, Squadrito G, Altavilla D: Reduction of Carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant. Free Radic Res. 2001, 34: 379-393.CrossRefPubMed
18.
Sato H, Takahashi T, Ide H, Fukushima T, Tabata M, Sekine F, Kobayashi K, Negishi M, Niwa Y: Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum. 1988, 31: 63-71.CrossRefPubMed
19.
Presti D, Scott JE: Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct. 1994, 12: 281-288.CrossRefPubMed
20.
Cortivo R, Brun P, Cardarelli L, O'Regan M, Radice M, Abatan-gelo G: Antioxidant effects of hyaluronan and its alpha-methyl-prednisolone derivative in chondrocyte and cartilage cultures. Semin Arthritis Rheum. 1996, 26: 492-501. 10.1016/S0049-0172(96)80030-8.CrossRefPubMed
21.
Albertini R, De Luca G, Passi A, Moratti R, Abuja PM: Chondroitin-4-sulfate protects high-density lipoprotein against copper-dependent oxidation. Arch Biochem Biophys. 1999, 365: 143-149. 10.1006/abbi.1999.1150.CrossRefPubMed
22.
Sela S, Shurtz-Swirski R, Shapiro G, Nasser L, Hamzi M, Shasha SM, Kristal B: Oxidative stress during hemodialysis: effect of heparin. Kidney Int. 2001, 78: S159-S163. 10.1046/j.1523-1755.2001.07830.x.CrossRef
23.
Cremer M: Type II collagen-induced arthritis in rats. In Handbook of Animal Models for the Rheumatic Diseases. Edited by: Greenwald RA, Diamond HS. 1988, Boca Raton, FL: CRC Press, 1: 17-27.
24.
Campo GM, Campo S, Ferlazzo AM, Vinci R, Calatroni A: Improved high-performance liquid chromatographic method to estimate aminosugars and its application to glycosaminoglycan determination in plasma and serum. J Chromatogr. 2001, 765: 151-160. 10.1016/S0378-4347(01)00427-3.CrossRef
25.
Larsson P, Kleinau S, Holmdahl R, Klareskog L: Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum. 1990, 33: 693-701.CrossRefPubMed
26.
Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993, 261: 1328-1330.CrossRefPubMed
27.
Ellman GL: Tissue sulphydryl groups. Arch Biochem Biophys. 1959, 82: 70-77. 10.1016/0003-9861(59)90090-6.CrossRefPubMed
28.
Lefkowitz DL, Gelderman MP, Fuhrmann SR, Grahams Starnes JD, Lefkowitz SS, Bollen A, Moguilevsky N: Neutrophil myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritis. Clin Immun. 1999, 91: 145-155. 10.1006/clim.1999.4696.CrossRef
29.
Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischaemic myocardium. J Pharmacol Methods. 1985, 14: 157-167. 10.1016/0160-5402(85)90029-4.CrossRefPubMed
30.
Bauerova K, Bezek A: Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen Physiol Biophys. 1999, 18: 15-20.PubMed
31.
VanderBorght A, Geusens P, Raus J, Stinissen P: The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum. 2001, 31: 160-175. 10.1053/sarh.2001.27736.CrossRefPubMed
32.
Knight JA: Free radicals, antioxidants, and the immune system. Ann Clin Lab Sci. 2000, 30: 145-158.PubMed
33.
Babior BM: Phagocytes and oxidative stress. Am J Med. 2000, 109: 33-44. 10.1016/S0002-9343(00)00481-2.CrossRefPubMed
34.
Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumars GK, Mukhtar H: Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA. 1999, 96: 4524-4529. 10.1073/pnas.96.8.4524.PubMedCentralCrossRefPubMed
35.
Corvo ML, Boerman OC, Oyen WJG, Van Bloois LV, Cruz MEM, Crommelin DJA, Storm G: Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta. 1999, 1419: 325-334. 10.1016/S0005-2736(99)00081-4.CrossRefPubMed
36.
Sakai A, Hirano T, Okazaki R, Okimoto N, Tanaka K, Nakamura T: Large-dose ascorbic acid administration suppresses the development of arthritis in adjuvant-infected rats. Arch Orthop Trauma Surg. 1999, 119: 121-126. 10.1007/s004020050374.CrossRefPubMed
37.
Darlington LG, Stone TW: Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr. 2001, 85: 251-269.CrossRefPubMed
38.
Ostrakhovitch EA, Afanas'ev IB: Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol. 2001, 62: 743-746. 10.1016/S0006-2952(01)00707-9.CrossRefPubMed
39.
40.
41.
Ferlazzo AM, Campo S, Vinci R, Ferrlazzo A, Calatroni A: Concentration and composition of serum and plasma glycosaminoglycans in domestic animal species. Comp Biochem Physiol. 1997, 118B: 935-942.CrossRef
42.
Calatroni A, Vinci R, Ferlazzo AM: Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behaviour of the protein-polysaccharide complexes in ultrafiltration and chromatographic procedures. Clin Chim Acta. 1992, 206: 167-180. 10.1016/0009-8981(92)90086-6.CrossRefPubMed
43.
Friman C, Nordstrom D, Eronen I: Plasma glycosaminoglycans in systemic lupus erythematosus. J Rheumatol. 1987, 14: 1132-1134.PubMed
44.
Laurent TC, Laurent UBG, Fraser JRE: Serum hyaluronan as a disease marker. Ann Med. 1996, 28: 241-253.CrossRefPubMed
45.
Radhakrishnamurthy B, Tracy RE, Dalferes ER, Berenson GS: Proteoglycans in human coronary arteriosclerotic lesions. Exp Mol Pathol. 1998, 65: 1-8. 10.1006/exmp.1998.2222.CrossRefPubMed
46.
Gambaro G, van der Woude FJ: Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol. 2000, 11: 359-368. 10.1159/000017267.PubMed
47.
Engstrom-Laurent A, Hallgren R: Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis. 1985, 44: 83-88.PubMedCentralCrossRefPubMed
48.
Roughley PJ: Articular cartilage and changes in arthritis: non-collagenous proteins and proteoglycans in the extracellular matrix of cartilage. Arthritis Res. 2001, 3: 342-347. 10.1186/ar326.PubMedCentralCrossRefPubMed
49.
Bjork J, Kleinau S, Tengblad A, Smedegard G: Elevated levels of serum hyaluronate and correlation with disease activity in experimental models of arthritis. Arthritis Rheum. 1989, 32: 306-311.CrossRefPubMed
50.
Van der Kraan PM, de Lange J, Vitters EL, van Beuningen HM, van Osch GJ, van Lent PL, van den Berg WB: Analysis of changes in proteoglycan content in murine articular cartilage using image analysis. Osteoarthritis Cartilage. 1994, 2: 207-214.CrossRefPubMed
51.
Thonar EJ, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, Katz R, Huff J, Kuettner KE: Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum. 1985, 28: 1367-1376.CrossRefPubMed
52.
Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell. 1991, 64: 867-869. 10.1016/0092-8674(91)90308-L.CrossRefPubMed
53.
Vestweber D, Blanks J: Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999, 79: 181-213.PubMed
54.
Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T: Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res. 2001, 305: 79-86. 10.1007/s004410100409.CrossRefPubMed
55.
Sconocchia G, Campagnano L, Adorno D, Iacona A, Cococcetta NY, Boffo V, Amadori S, Casciani CU: CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood. 2001, 97: 3621-3627. 10.1182/blood.V97.11.3621.CrossRefPubMed
56.
Syrokou A, Tzanakakis G, Tsegenidis T, Hjerpe A, Karamanos NK: Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif. 1999, 32: 85-99. 10.1046/j.1365-2184.1999.32230085.x.CrossRefPubMed
57.
Foschi D, Castoldi L, Radaelli E, Abelli P, Calderini G, Rastrelli A, Mariscotti C, Marazzi M, Trabucchi E: Hyaluronic acid prevents oxygen free-radical damage to granulation tissue: a study in rats. Int J Tissue React. 1990, 12: 333-339.PubMed
58.
Arai H, Kashiwagi S, Nagasaka Y, Uchida K, Hoshii Y, Nakamura K: Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophys. 1999, 367: 1-8. 10.1006/abbi.1999.1222.CrossRefPubMed
59.
Albertini R, Passi A, Abuja PM, De Luca G: The effect of glycosaminoglycans and proteoglycans on lipid peroxidation. Int J Mol Med. 2000, 6: 129-136.PubMed
60.
Graf J, Neusel E, Schneider E, Niethard FU: Intra-articular treatment with hyaluronic acid in osteoarthritis of the knee joint: a controlled clinical trial versus mucopolysaccharide polysulfuric acid ester. Clin Exp Rheumatol. 1993, 11: 367-372.PubMed
61.
Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG: Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron. 1994, 67: 346-350.CrossRefPubMed
62.
Shankland WE: The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients. Cranio. 1998, 16: 230-235.PubMed
63.
Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD: Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med. 1999, 164: 85-91.PubMed
64.
Beren J, Hill SL, Diener-West M, Rose NR: Effect of preloading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats. Exp Biol Med. 2001, 226: 144-151.
65.
Jira W, Spiteller G, Richter A: Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids. 1997, 87: 81-89. 10.1016/S0009-3084(97)00030-3.CrossRefPubMed
66.
Wills ED: Evaluation of lipid peroxidation in lipid and biological membranes. In Biochemical Toxicology; a Practical Approach. Edited by: Snell K, Mullock B. 1987, Oxford: IRL Press, 127-152.
67.
Kizilntuc A, Cogalgil S, Cerrahoglu L: Carnitine and antioxidants levels in patients with rheumatoid arthritis. Scand J Rheumatol. 1998, 27: 441-445. 10.1080/030097498442271.CrossRef
68.
Hassan MQ, Hadi RA, Al-Rawi ZS, Padron VA, Stohs SJ: The glutathione defense system in the pathogenesis of rheumatoid arthritis. J Appl Toxicol. 2001, 21: 69-73. 10.1002/jat.736.CrossRefPubMed
69.
Feldmann M, Brennan FM, Foxwell BM, Maini RN: The role of TNF-alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 2001, 3: 188-199.CrossRefPubMed
70.
Volpi N, Tarugi P: Influence of chondroitin sulfate charge density, sulfate group position, and molecular mass on Cu++-mediated oxidation of human low-density lipoproteins: effect of normal human plasma-derived chondroitin sulfate. J Biochem (Tokyo). 1999, 125: 297-304.CrossRef
71.
Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G: Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung. 1990, 40: 319-323.PubMed
72.
Gustafson S, Bjorkman T: Circulating hyaluronan, chondroitin sulphate and dextran sulphate bind to a liver receptor that does not recognize heparin. Glycoconj J. 1997, 14: 561-568. 10.1023/A:1018528308132.CrossRefPubMed
73.
Omata T, Itokazu Y, Inoue N, Segawa Y: Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung. 2000, 50: 148-153.PubMed
Metadata
Title
Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats
Authors
Giuseppe M Campo, PhD
Angela Avenoso
Salvatore Campo
Alida M Ferlazzo
Domenica Altavilla
Alberto Calatroni
Publication date
01-06-2003
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2003
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar748

Other articles of this Issue 3/2003

Arthritis Research & Therapy 3/2003 Go to the issue

Review

Degeneration of the intervertebral disc

Viewpoint

New insights into integrin signalling: implications for rheumatoid arthritis synovial fibroblasts

Review

CD44 in rheumatoid arthritis

Review

Autoantibodies in vasculitis

Review

Behçet's disease

Research article

Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits